CYAD Celyad Oncology SA

0.1766USD0.1610 EUR · EBR-8.00%Mkt Cap: 13.22M USDP/E: 2.01

Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it …

Institutional holders1 on file

Key Statistics

Company
Market Cap13.22M USD
Enterprise Value7.77M USD
Revenue (TTM)7.68K USD
Gross Profit14.26K USD
Net Income (TTM)910.34K USD
Revenue/Share0.00 USD
Last Price0.1766 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees4
CountryBE
SectorHealthcare
IndustryBiotechnology
ISINBE0974260896
Valuation
P/E (Trailing)2.01
P/E (Forward)0.25
PEG—
EV/EBITDA9.14
EV/Revenue1012.24
P/S1722.31
P/B5.75
EPS (TTM)0.09 USD
EPS (Forward)0.70 USD
52W Range
0.15364% of range0.7129
52W High0.7129 USD
52W Low0.1536 USD
Profitability
Gross Margin61.90%
Oper. Margin13300.00%
EBITDA Margin11071.43%
Profit Margin3952.38%
ROE34.06%
ROA19.31%
ROIC-184.62%
ROCE-54.19%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.57M USD
CapEx (TTM)—
FCF Margin-16280.36%
FCF Yield-9.45%
Net Debt-132.71K USD
Net Debt/EBITDA-0.16
Net Debt/FCF—
Balance Sheet
Debt/Equity0.00
Current Ratio0.94
Quick Ratio0.91
Book Value/Sh0.03 USD
Cash/Share0.0033 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.74.88M
Float14.16M
Insiders10.28%
Institutions55.49%
Technical
SMA 500.2327 (-24.1%)
SMA 2000.3016 (-41.5%)
Beta1.23
S&P 52W Chg12.00%
Avg Vol (30d)14.24K
Avg Vol (10d)30.33K
Technical Indicators
RSI (14)40.3
MACD-0.0158
MACD Signal-0.0147
MACD Hist.-0.0011
BB Upper0.2509 USD
BB Middle0.2023 USD
BB Lower0.1537 USD
BB Width48.03%
ATR (14)0.0158 USD
Vol Ratio (20d)0.27x

About Celyad Oncology (EBR: CYAD)

›

Celyad Oncology (EBR: CYAD) is listed on Euronext Brussels, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 4 employees.

The shares were at 0.1610 EUR on 19 November 2026, down 19.5% over 52 weeks. Its 52-week range is 0.1400 EUR to 0.6500 EUR: the price is 75.2% below the high and 15.0% above the low.

At a market capitalisation of 12.06M EUR, it trades at 2.0 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a discount of 94% for CYAD.

Celyad Oncology reports return on equity of 34.1%.

It holds more cash than debt, a net cash position of 121.00K EUR. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.